Prestron

Quick links to important sections

Prestron

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prestron

What is Prestron? Overview and Quick Facts

Property Description
Active Ingredient Chlormadinone acetate (CMA)
Form Oral tablets
Pharmacological Class Progestogen (Synthetic)
General Purpose Hormonal regulation and control
Origin Synthetic derivative of Progesterone
Differentiating Feature Notable antiandrogenic activity

Defining Prestron: A Progestogen and Antiandrogen

Prestron is a pharmaceutical preparation containing the active ingredient Chlormadinone acetate (CMA), which is classified as a steroidal progestogen (or progestin). This medicine is a synthetic derivative of the body's natural hormone progesterone, structurally modified for stable oral administration. The core function of Chlormadinone acetate places it within the G03DB06 pharmacological class of Pregnadien derivatives. Its powerful antiandrogenic activity sets it apart from many other standard progestogens and serves as a key differentiator in its therapeutic profile. Chlormadinone acetate actively blocks the effects of androgens (male hormones).


Composition and Form: The Chlormadinone Acetate Tablet

The physical form of Prestron is typically an oral tablet, designed for systemic delivery of the Chlormadinone acetate into the bloodstream via the oral route of administration. The medicine is available as both a single-ingredient product and, more commonly, as a combination hormonal preparation—a fixed-dose combination pill—where the active ingredient is paired with an estrogen to enhance its effects. For instance, combination products containing this substance are often used for women requiring contraception. The active ingredient is formulated within solid oral tablets using standard pharmaceutical excipients. The substance has a high affinity for the progesterone receptor, which is essential for its function as a progestogen.


General Purpose: What Role Does Prestron Serve?

The general purpose of Prestron is to facilitate hormonal regulation and stabilize the female reproductive system through its specialized actions. By utilizing its progestational effect and antigonadotropic action (inhibiting the release of gonadotropins), the medicine helps to create a controlled hormonal environment. This regulating capacity is essential for achieving hormonal contraception and managing symptoms associated with certain hormone-influenced gynecological disorders. The added benefit of its antiandrogenic effect means it can help to mitigate physical manifestations linked to excess androgen activity within the body.

What side effects are possible with Prestron?

Prestron's safety profile is defined by official regulatory documentation, which includes a Boxed Warning—the most serious warning issued by the U.S. Food and Drug Administration (FDA)—and information on common, serious, and population-specific adverse reactions.

Serious Safety Concerns and Contraindications

  • Fetal Toxicity: A Boxed Warning alerts to the risk of injury and death to the developing fetus. The drug must be discontinued as soon as a pregnancy is detected.
  • Angioedema: Rapid swelling of the face, limbs, lips, tongue, glottis, and/or larynx is a risk and requires immediate medical attention. The drug is contraindicated in patients with a history of angioedema related to previous therapy with an ACE inhibitor or ARB.
  • Hypotension and Syncope: Severe low blood pressure (hypotension) may occur, particularly with initial dosing, which can lead to fainting (syncope).
  • Contraindications: Prestron is contraindicated for co-administration with ACE inhibitors or with aliskiren in patients with diabetes. It is also not recommended in patients with severe hepatic impairment.

Common Adverse Reactions

Based on clinical data, common adverse reactions (occurring in ge 5% of patients) primarily involve the cardiovascular and renal systems and electrolyte balance. These include:

  • Hypotension (low blood pressure)
  • Hyperkalemia (high potassium levels)
  • Cough
  • Dizziness
  • Renal failure/Impaired renal function

Required Safety Monitoring

Regulatory documentation mandates high-level monitoring for certain risks, including regular assessment of renal function and serum potassium levels, especially in patients who may be susceptible to hyperkalemia. Ongoing observation for signs and symptoms of angioedema and hypotension is also required during therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information classifies acute overdosage of Prestron (Chlormadinone acetate) as generally not associated with serious adverse effects, reflecting a wide therapeutic index for this hormonal component.


Documented Overdose Scope

Element Official Regulatory Statement
Documented Manifestations Nausea, vomiting, and withdrawal bleeding (in females) are the most commonly documented clinical signs. Mild drowsiness or fatigue may also be observed.
Population-Specific Notes Overdose symptoms, including gastrointestinal effects, have been reported in both adults and children.
Emergency-Response Statement Treatment, if necessary, must be symptomatic and supportive. No specific antidote is known for the active substance.
When Help Is Required Medical attention should be sought if the overdose symptoms are severe, persistent, or cause significant concern.

Overdose Classification and Management

Official Overdose Statements:

  • Acute overdosage is consistently documented as not associated with serious adverse effects.
  • No specific antidote is known for the active ingredient.
  • Management is strictly defined as symptomatic and supportive treatment.

Connection to the Overall Overdose Profile: Regulatory documents characterize the acute overdose profile of Prestron as benign, primarily resulting in mild gastrointestinal and transient uterine manifestations. Due to the expected low systemic severity and the absence of a known specific antidote, the official guidance emphasizes supportive care and mandates that medical help should be sought only for symptoms that are persistent or unusually severe.

Therapeutic Uses of Prestron

What Prestron Treats: Main Uses and Benefits

The therapeutic role of Prestron (Chlormadinone acetate) is commonly used for hormonal contraception (pregnancy prevention). This medication is also commonly used to help manage significant symptoms related to heightened physiological activity that interfere with daily functioning, particularly in scenarios where its antiandrogenic effect is considered relevant.

Prestron is considered relevant for easing challenging manifestations across several categories of conditions, including androgen-related skin and hair issues, irregular cycle patterns, heavy menstrual bleeding (HMB), and pronounced pain associated with dysmenorrhea. Its use may also assist in supporting the management of chronic hormone-influenced disorders like endometriosis and certain aspects of Polycystic Ovary Syndrome (PCOS).

The therapeutic approach is focused on supportive relief, as the medication is applied in clinical contexts that involve acute or unstable symptom patterns. For patients, this use contributes to improved comfort, helping them cope more steadily with symptom fluctuations and supporting general well-being during symptomatic phases.

“Prestron is often used when a patient requires both effective contraception and support for hormonally driven skin and hair manifestations.”


Quick Fact: Relief for Hormone-Influenced Skin Symptoms

Regulatory References

  1. Belara Summary of Product Characteristics

Eligibility and Restrictions for Use

The eligibility for Prestron (Chlormadinone acetate) is strictly defined by official regulatory documents, which classify population groups based on absolute contraindications and conditional restrictions. The medicine is primarily authorized for use in females of reproductive potential who are post-menarche. The active ingredient is also documented for use in postmenopausal women as part of Hormone Replacement Therapy (HRT) regimens.

Populations Who Must Not Use Prestron (Contraindicated)

Eligibility Status Key Restrictions (Official Regulatory Labeling)
Absolute Contraindication History of thromboembolic disorders (VTE or ATE), severe vascular risk factors (e.g., severe hypertension, diabetes with vascular symptoms), known thrombophilia, or current/history of breast cancer, liver tumors, or meningioma. Also prohibited in known or suspected pregnancy and in cases of severe hepatic disease until liver function is restored.

Restricted and Age-Based Eligibility

Population Group Regulatory Status
Lactating/Breastfeeding Women Use is not recommended.
Pediatric Use Restricted to post-menarche females; use is not established in pre-menarche children.
Surgical/Immobilization Risk Mandatory discontinuation four weeks before major elective surgery or during prolonged immobilization.

These rules establish definitive boundaries for use, based solely on official government-approved prescribing information.

What should I know about interactions with other medicines?

Prestron Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Prestron (Chlormadinone acetate) based on government regulatory sources.

Contraindicated Combinations

Co-administration of Prestron combination products is formally prohibited with specific antiviral regimens used to treat Hepatitis C. These combinations are:

  • Medicines containing Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir.
  • Medicines containing Glecaprevir/Pibrentasvir.
  • Medicines containing Sofosbuvir/Velpatasvir/Voxilaprevir.

This restriction is documented due to the risk of elevated liver enzyme levels when these substances are used together.

Medicines that Reduce Drug Exposure

Regulatory documents list several medicines that can reduce the concentration of Prestron's active components in the bloodstream by increasing the rate at which they are cleared from the body. These agents include:

  • Anticonvulsants (e.g., Phenytoin, Carbamazepine, Topiramate).
  • Anti-infectives (e.g., Rifampicin, certain HIV/HCV inhibitors like Ritonavir).
  • The herbal product St. John's Wort (Hypericum perforatum).

Other Documented Interactions

The estrogen component of Prestron can alter the binding capacity of certain blood proteins. This documented effect may require a dose adjustment for co-administered replacement therapies, such as thyroid hormones and cortisol therapy. Following treatment with the contraindicated antiviral regimens, regulatory documents state that Prestron may be restarted two weeks after the antiviral course is complete.

Mechanism of Action

The mechanism of action of Chlormadinone acetate (CMA) is defined by its selective, dual-action modulation of the body's steroid hormone systems, affecting both central endocrine regulation and peripheral tissue response.


Central Hormonal Axis Modulation

CMA acts as an agonist at the Progesterone Receptor (PR), triggering negative feedback on the Hypothalamic-Pituitary-Ovarian (HPO) axis. This results in antigonadotropic action that causes the suppression of the Luteinizing Hormone (LH) surge, which is necessary for ovulation.


Peripheral Androgen Receptor Blockade

CMA’s activity includes competitive antagonism at the Androgen Receptor (AR) in peripheral tissues. By occupying the AR, CMA prevents endogenous androgens (like DHT) from activating the receptor, thereby altering the cellular response and downstream effects of androgen signaling in those tissues.


Reproductive Tissue Transformation

The PR agonism simultaneously causes local, tissue-level changes. It shifts the endometrium to a decidualized state, which is structurally unreceptive to implantation, and increases the viscosity of cervical mucus. This alteration creates a physical and chemical barrier that hinders sperm motility and passage.

Dosage and Administration Information

How to Use Prestron

Prestron, which contains Chlormadinone acetate (CMA), is administered via the oral route as a tablet. The specific dosing and schedule depends on the intended usage pattern.

Administration Route and Dosing

Chlormadinone acetate is available in multiple oral tablet strengths. When used as a component of a fixed-dose combination pill, the standard daily dose is 2 mg of CMA per active tablet. For other gynecological purposes using the single-ingredient preparation, the dosage ranges from 2 mg to 10 mg per day. Regardless of the specific application, the treatment principle is the administration of the lowest effective dose.

Schedule and Timing

The medicine is taken once daily. For ongoing hormonal regulation, the drug follows a cyclic regimen, typically involving 21 days of active tablets followed by a 7-day hormone-free interval before the next cycle begins. To ensure consistent systemic levels, the dose is taken at the same time every day. The tablets are swallowed in the sequence directed on the packaging and can be taken with liquid without regard to meals.

For higher single-ingredient doses, such as those at the 5 mg or 10 mg strength, the medication is typically intended for use for the shortest duration possible.

Recent Clinical Evidence

Research evidence / Overview of Studies for Prestron

Evidence for Use in Hormonal Contraception

Prestron (Chlormadinone acetate, CMA) was studied for pregnancy prevention through large, non-comparative clinical trials and extensive observational research. The main outcomes measured included the Pearl Index (a standard method used in research to determine contraceptive function) and biological indicators related to the inhibition of ovulation. Data show patterns related to cycle stability and its intended contraceptive function over the observed periods.


Evidence for Hormonally-Related Symptoms

Research has specifically examined the antiandrogenic properties of CMA in the context of skin and hair conditions like acne and hirsutism. Randomized Controlled Trials (RCTs) monitored changes in acne lesion counts and severity scores over observation periods. Studies also explored its use regarding dysmenorrhea (menstrual pain) and irregular cycle patterns, tracking how pain and cycle stability evolved in the observed populations.


Evidence in Specific Gynecological Contexts

Studies have examined the use of the combined product in managing androgen-related manifestations of Polycystic Ovary Syndrome (PCOS). Furthermore, the active ingredient was studied in the context of other gynaecological disorders like endometriosis; however, much of the older evidence for these specific uses involves higher-dose, CMA-only formulations, meaning comparative evidence for the lower-dose combination product is limited.


Long-Term Research and Follow-up Durations

Many clinical evaluations have observed women for up to 21 to 24 cycles (approximately two years) to assess contraceptive function and cycle stability. This research provides insight into short-term and intermediate outcomes. However, long-term effects are not fully established or well-characterized by structured, comparative research extending over many years.


Research Gaps and Areas of Uncertainty

The available evidence highlights what is known and what is still uncertain. While studies describe patterns of change across various symptoms, comparative evidence is lacking in some areas, particularly large-scale RCTs comparing the CMA combination to non-treatment for symptomatic assessment. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Belara 0.03 mg/2 mg film-coated tablets - Summary of Product Characteristics (Used for dosing and indications context)
  2. ATC Code G03DB06: Chlormadinone and estrogen (WHO Anatomical Therapeutic Chemical Classification)
  3. Efficacy and safety of a combined oral contraceptive containing chlormadinone acetate and ethinylestradiol in acne and hirsutism: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Prestron (FAQ)

Q: What should be done in general terms if a dose of Prestron is missed?

The steps required if a dose is missed are clearly defined in the official prescribing information. The procedure depends on how much time has passed since the scheduled dose and the specific week of the treatment cycle. Following the specific protocol is noted in regulatory documents as important for maintaining the intended effects, such as hormonal regulation.

Q: Does Prestron have a known interaction with grapefruit or grapefruit juice?

Official product information, based on scientific understanding, indicates that grapefruit may affect how the body processes the estrogen component of this medicine. This potential change could theoretically increase the concentration of the estrogen component in the body, which might increase the chance of experiencing estrogen-related side effects.

Q: Can Prestron be taken alongside common over-the-counter pain relievers?

According to regulatory data for combination hormonal contraceptives and acetaminophen, the contraceptive component may slightly alter how the body processes the pain reliever. Official information suggests this interaction is not typically associated with clinical significance when the pain reliever is used at standard, non-excessive dosages.

Q: Are there official warnings about Prestron and driving or operating machinery?

Official documents do not include an explicit prohibition against driving or operating machinery. However, the common adverse reactions listed in the prescribing information include dizziness and hypotension (low blood pressure). The presence of these effects suggests they may have an impact on a person's ability to safely operate machinery.

Q: How is the risk of allergic reactions to Prestron described?

The official product information specifically describes a severe allergic-type reaction called angioedema. This is identified as a serious risk involving rapid swelling of the face, tongue, and throat, which requires immediate medical attention.

Q: What kind of monitoring tests (e.g., blood work) may be recommended while on Prestron?

Regulatory documentation mandates the monitoring of certain parameters during therapy with Prestron. This includes regular assessment of renal function and serum potassium levels, which are typically checked via blood tests. Ongoing observation for signs of hypotension and angioedema is also required.

Q: Is Prestron safe for patients with a pre-existing condition like high blood pressure?

The medicine is formally contraindicated, meaning it should not be used, in patients with severe hypertension or other severe vascular risk factors. Furthermore, regulatory documents for this class of medicine note that a blood pressure increase has been reported in women taking hormonal contraceptives.

Q: Are there specific warnings for older adults (geriatric population) taking Prestron?

The medicine is generally restricted to females of reproductive potential for contraception. However, the active ingredient is also documented in official labeling for use in postmenopausal women as part of Hormone Replacement Therapy regimens. No unique warnings distinct from general contraindications are typically provided for the geriatric population in the available regulatory summaries.

Q: Is Prestron considered a medication for long-term or short-term use?

The determination of short-term versus long-term use depends on the formulation being administered. The high-dose, single-ingredient preparation is officially constrained to the shortest duration possible. Conversely, the combination product used for contraception is administered in a cyclic regimen intended for ongoing, long-term hormonal regulation.

Q: What does the official documentation say about Prestron causing weight gain or weight loss?

Weight changes are not always listed among the most common adverse reactions. However, some clinical data has reported weight gain as a potential side effect associated with the use of the medicine's active components. Official documentation sometimes tracks this as a monitored change during clinical trials.

Q: Can Prestron cause headaches?

Official clinical data for Prestron identifies headache and migraine as commonly reported adverse events. This information is derived from clinical trials and observational data collected during the study of the product.

Q: How is Prestron's safety profile described for pregnant or breastfeeding women?

The regulatory documents include a Boxed Warning regarding the risk of injury and death to the developing fetus, and the medicine must be discontinued upon detected pregnancy. Use in women who are breastfeeding is also officially not recommended by regulatory authorities.

Q: How long does it usually take to notice the effects of Prestron?

The amount of time required to notice the effects of Prestron depends on its intended purpose. For contraception, the intended hormonal effect is described as starting quickly when the medicine is initiated according to official instructions. For anti-androgenic effects, such as treating skin conditions, improvements have been observed over a period of several treatment cycles.

Q: Is it possible to have no side effects while taking Prestron?

Clinical trial data describing the medicine as generally 'well tolerated' indicates that some individuals may experience few or no side effects. Official reports also suggest that for many women who initially experienced minor side effects, those effects were observed to decrease or disappear after continuing treatment.

Q: What are the effects of taking Prestron in the morning vs. at night?

The official administration schedule requires the medicine to be taken once daily at the same time every day to ensure consistent levels of the substance in the bloodstream. Regulatory documents do not specify a preferred time of day (morning or night) relative to potential benefits or side effects.

Q: Is there a link between Prestron and changes in mood or anxiety levels?

Clinical research evidence suggests patterns in observed populations where the use of this medicine's active components was reported alongside a reduction in symptoms related to mood swings, anxiety, and depression. This finding is based on documented patterns of change in research studies.

Q: Are the side effects of Prestron dose-dependent?

Regulatory documentation identifies that the risk of a rare, serious side effect, meningioma, increases with increasing dose and duration of treatment. This information indicates a documented risk that is dependent on the dose and duration of exposure, particularly with the high-dose single-ingredient formulations.

How should Prestron be stored and disposed of?

How to Store and Dispose of Prestron

The storage and disposal of Prestron (Chlormadinone acetate oral tablets) must follow official guidelines to maintain stability and ensure safety.

Required Storage Conditions

Prestron should be stored in a cool and dry place at room temperature, away from direct sunlight, heat, and moisture. It is required that the medicine be kept tightly closed in its original packaging.

Safety and Disposal

The product must be stored out of the sight and reach of children and securely locked up.

Disposal of unused or expired Prestron and its containers must be performed in accordance with local, regional, and national regulations. To prevent environmental harm, the product must not be allowed to enter sewers or water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prestron found in:

A-Z Index: